Aspergillosis
is a medical disorder in which aspergillus mould, which is commonly found in
the environment, causes infection or an allergic reaction. Allergic
bronchopulmonary aspergillosis, allergic aspergillus sinusitis, aspergilloma,
chronic pulmonary aspergillosis, invasive aspergillosis, and cutaneous (skin) aspergillosis
are all kinds of aspergillosis. According to the CDC, allergic bronchopulmonary
aspergillosis affects 15% of cystic fibrosis patients, 2.5 percent of asthma
patients, and 2.5 percent of tuberculosis patients. As a result of the increase
in the number of instances of aspergillosis and the development in treatment
choices, the Aspergillosis treatment
market is expected to grow rapidly. Furthermore, increased public awareness
about aspergillosis treatment, rising demand for treatment, rising aspergillosis
incidence, and advancements in aspergillosis diagnosis methods are driving the
aspergillosis treatment market.
The Aspergillosis
treatment market is now undergoing intensive research and
development, with a large number of new products being introduced. This pushes
manufacturers to meet the growing demand from patients for efficient and
effective treatment options. The Aspergillosis
treatment market is one of the most concentrated, with key industry players
such as Pfizer, Inc., Novartis AG, Astra Zeneca plc, Abbott Laboratories, Inc.,
Merck & Co., and GlaxoSmithKline holding considerable market share. The
majority of firms devote significant research resources to the development of
novel drug regimens, as well as substantial financial support. This has
contributed to the market's expansion. As a result, the huge unmet need for
aspergillosis curative treatment will create a considerable market potential.
Emerging economies in Asia, where illness prevalence is relatively high, are
projected to fuel growth in the worldwide aspergillosis market.
 |
| Aspergillosis Treatment Market |
Regional Insights into the
Aspergillosis Treatment Market
The Aspergillosis
treatment market into North America, Latin America, Europe, Asia Pacific,
the Middle East, and Africa. Because of increased government initiatives for
identifying and treating infection, the Aspergillosis
treatment market in North America is projected to keep a dominating
position. In 2016, the Infectious Diseases Society of America (IDSA) updated
their guidelines for identifying and treating Aspergillus species infections.
The publication provides recommendations for non-culture-based Aspergillus infection
detection and discourages the use of combination antifungal medication for
primary care. Isavuconazole, a novel antifungal medicine licenced by the US
Food and Drug Administration in March 2015 to treat mucormycosis and
aspergillosis, is also defined in the guidelines. The market for Aspergillosis
therapy is expected to grow significantly over the forecast period, owing to an
increase in the number of untreated patients in Asia Pacific.
Comments
Post a Comment